Yasmin
Phase 3Small molecule
BayerYasmin is one of 123 small molecule programs targeting Contraception. It is currently in Phase 3.
4
Indications
14
Total Trials
0
Active Trials
122
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Lupron
AbbViePhase 3
Revia
TevaPhase 3
Leuprorelin
TakedaPhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Trental
VValidus Pharmaceuticals
Phase 3
Firmagon
FerringPhase 3
Estradiol/norethindrone Acetate
AbbViePhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome3 trials
Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Unknown status·—·Phase 1·NCT01603745·10 enrolled
Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome
Completed·—·Phase 3·NCT01581814·99 enrolled
Treatment1 trial
Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome
Completed·—·Phase 3·NCT02089620·210 enrolled
Adenomyosis1 trial
Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri
Unknown status·—·Phase 1·NCT03037944·32 enrolled
Female1 trial
7 more indications
Oral1 trial
Hemostasis1 trial
Contraception1 trial
Endometriosis1 trial
Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis
Unknown status·—·Phase 2/3·NCT04256200·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yasmin. EMBL-EBI & Wellcome Sanger Institute.
- [4]